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Objectives. We sought to prospectively investigate whether 
genetic variation at the angiotensin-converting e zyme gene locus 
defined by an insertion (I)/deletion (D) polymorphism influences 
the risk of myocardial infarction or prognosis after infarction, or 
both. 
Background. It has been suggested that he deletion allele of the 
angiotensin-converting enzyme gene, and specifically the DD 
genotype, may increase the risk of myocardial infarction, although 
previous tudies have produced conflicting reports. No studies 
have yet examined the effect of UD polymorphism on survival after 
infarction. 
Methods. Angiotensin-converting e zyme genotypes in 684 pa- 
tients with myocardial infarction recruited at the time of the acute 
event hrough coronary care units in two centers were compared 
with those of 537 control subjects recruited from the base popu- 
lations. All patients were followed up to assess the impact of the 
angiotensin-converting e zyme genotype on prognosis. 
Results. We found no difference (p = 0.89) in the genotype 
distribution between patients and control subjects (patients DD 
31%, ID 47%, II 22%; control subjects DD 30%, ID 48%, II 22%). 
The odds ratio for myocardial infarction for DD compared with 
II/ID genotype adjusted for age, gender and center was 1.16 (95% 
confidence interval [CI] 0.82 to 1.65, p = 0.44). The study had 90% 
power to detect a1.5-fold increase in risk of myocardial infarction 
associated with the DD genotype. For one center, data were 
available for other risk factors (hypertension, diabetes, angina, 
previous myocardial infarction, smoking, body mass index, total 
and high density lipoprotein cholesterol) in both patients and 
control subjects. In a stepwise logistic regression analysis the 
odds ratio for DD versus ID/II genotypes remained nonsignificant 
(1.44, 95% CI 0.84 to 2.46, p = 0.20) for these subjects. Over a 
median follow-up eriod of 15 months (range 3 to 22), 155 patients 
(22.7%) died. There was no difference in mortality between 
subjects with the DD genotype and those with ID/II genotypes. 
(21.8% vs. 23.1%, p = 0.25). Likewise, there was no difference in 
the distribution of survival times in the two groups (p = 0.62). The 
study had 70% power to detect a 1.5-fold increase in mortality 
during follow-up associated with the DD genotype. 
Conclusions. We conclude that in the groups studied, genetic 
variation at the angiotensin-converting e zyme gene locus defined 
by I/D polymorphism does not significantly influence ither the 
risk of or the short- to medium-term prognosis after myocardial 
infarction. 
(JAm CoU Cardiol 1996;28:338-44) 
Although epidemiologic studies have identified several impor- 
tant risk factors for coronary artery disease and myocardial 
infarction, including smoking, hypertension, diabetes and hy- 
percholesterolemia, it is readily apparent from clinical practice 
that the known factors only partly explain the risk (1). A 
positive family history of early myocardial infarction is also a 
strong indicator of increased risk (2,3). Some of this increased 
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familial risk may reflect a sharing of environmental risk factors 
or a shared tendency to risk factors with a genetic omponent 
such as hypertension a d hyperlipidemia (4); however, recent 
interest has focused on other inherited factors that may 
directly influence the risk of myocardial infarction. In partic- 
ular, since the report of Cambien et al. (5), attention has 
focused on the gene for angiotensin-converting e zyme. 
Angiotensin-converting enzyme is a ubiquitous endothe- 
lially located carboxypeptidase that catalyzes the activation of 
angiotensin I to angiotensin II and the inactivation of brady- 
kinin to kinin degradation products (6). Both angiotensin II 
and bradykinin are powerful vasoactive molecules with multi- 
ple short- and long-term effects on the cardiovascular system. 
Therefore, with its pivotal role in two important cardiovascular 
hormonal regulatory systems, the renin-angiotensin ystem and 
the kallikrein-kinin system, angiotensin-converting enzyme has 
the potential to have an important impact on cardiovascular 
structure and function (6). 
The gene for angiotensin-converting e zyme is located on 
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chromosome 17, and is characterized by an insertion/deletion 
polymorphism based on the presence (insertion [I]) or absence 
(deletion [D]) within intron 16 of a 287-base pair alu repeat 
sequence, resulting in three genotypes (DD and II homozy- 
gotes and ID heterozygotes) (7). The DD genotype is associ- 
ated with an -two-fold increase in plasma angiotensin- 
converting enzyme activity over that of the II genotype, with 
intermediate l vels in the heterozygotes (7). In 1992, in a 
retrospective multicenter, case-control study, Cambien et al. 
(5) reported that the frequency of the DD genotype was also 
increased in patients recruited 3 to 9 months after myocardial 
infarction. The frequency was particularly increased in patients 
considered to be at low risk of infarction on the basis of body 
weight and apolipoprotein B levels. Since then, studies both 
supporting the finding (8-16) as well as those questioning the 
veracity of the association (17-19) have been published, lead- 
ing to uncertainty about he importance of the polymorphism. 
A major limitation of several studies (5,14,17,19) has been the 
recruitment of patients with myocardial infarction several 
months if not years after the event, raising the possibility that 
selective survival may have influenced the results. In addition, 
no study has specifically examined the effect of the angiotensin- 
converting enzyme genotype on survival after myocardial in- 
farction. This is potentially a very important issue, not only 
because it may identify a novel factor influencing prognosis 
after myocardial infarction but also because angiotensin- 
converting enzyme inhibitors have been shown to improve 
survival after infarction (20-22) and possibly decrease the 
incidence of recurrent infarction (20). In this study, we there- 
fore examined the association of the angiotensin-converting 
enzyme DD genotype with myocardial infarction in patients 
recruited at the time of admission with acute infarction and 
also investigated the influence of the angiotensin-converting 
enzyme genotype on prognosis up to 22 months after infarction 
in this group. 
Methods  
Study group. The study patients were recruited from pa- 
tients admitted to the coronary care units at the Leicester 
Royal Infirmary, Leicester and the Royal Hallamshire Hospi- 
tal, Sheffield who satisfied the World Health Organization 
criteria for myocardial infarction in terms of symptoms, erum 
cardiac enzyme elevations or electrocardiographic (ECG) 
changes (23). The two coronary care units, each serving 
-300,000 persons, account for the majority (>65%) of pa- 
tients admitted with myocardial infarction in the two cities. 
The period of recruitment was between July 1993 and April 
1994 in Leicester and between May 1993 and December 1994 
in Sheffield. In both centers, >95% of eligible patients were 
recruited. 
In Leicester, control subjects were recruited from adult 
visitors of patients with noncardiovascular illnesses on general 
medical, surgical, orthopedic and obstetric wards to provide 
subjects likely to be representative of the source population 
from which the study patients came. Subjects who reported a
history of coronary heart disease were identified but not 
excluded. Patients and control subjects completed a standard 
questionnaire about their personal history, had their height 
and weight measured and provided blood samples for genotype 
analysis and measurement of serum total and high density 
lipoprotein cholesterol. In Sheffield, a local hospital staff and 
student population was used as the control group. Age and 
gender were recorded and blood was taken for genotype 
analysis only. The studies in both centers were approved by the 
respective local clinical research ethics committees. 
Determination of angiotensin-converting enzyme geno- 
types. Deoxyribonucleic acid (DNA) was prepared from a 
small aliquot of whole blood collected in ethylenediamine 
tetraacetic acid by using a DNA extraction matrix (Instagene, 
Biorad, Hemel Hempstead, Hertfordshire, England). Geno- 
types were determined by polymerase chain reaction amplifi- 
cation of the I/D region of the angiotensin-converting e zyme 
gene using oligonucleotide primers and resolving the amplified 
products (I allele = 490 base pairs, D allele = 190 base pairs) 
on 1.5% agarose gels containing ethidium bromide as previ- 
ously described (24) with modifications to prevent mistyping of 
I/D individuals as DD homozygotes (25). Blank controls were 
routinely included with each set of amplifications to exclude 
contamination. Genotypes were determined without knowl- 
edge of the case-control status and, as a further check, 20% of 
subjects were randomly chosen to undergo repeat genotyping 
with the use of freshly prepared DNA. In all cases the 
previously assigned genotype was confirmed. 
Biochemical measurements. Serum total and HDL choles- 
terol were measured by using a Kodak Ektachem E700 CXR 
Automatic Analyzer in a quality-controlled hospital biochem- 
istry laboratory. In patients, the first blood sample taken after 
admission was used for the analysis. 
Patient follow-up. Information on patients who died during 
their stay in the coronary care unit or in the hospital was 
obtained from the clinical notes. All patients who were dis- 
charged were flagged in the United Kingdom National Health 
Service Central Register for notification to us of their death. 
Through this mechanism a 100% mortality follow-up was 
obtained. Follow-up was carried out to April 1995. 
Statistical analysis. Distribution of angiotensin-converting 
enzyme I/D genotypes and qualitative risk factors between 
patients and control subjects or different genotype groups were 
compared by using the chi-square test. Quantitative sample 
means were compared by analysis of variance. Odds ratios 
and 95% confidence intervals (CI) estimating the relative 
risk of myocardial infarction associated with the DD genotype 
were calculated by using the Mantel-Haenszel method with 
stratification, where described, for age, gender and center. 
Logistic regression was used to analyze the influence of other 
factors on the odds ratio. Mortality rates at specified time 
points between patients with different genotypes were com- 
pared by the Mantel-Haenszel method and survival time 
distributions were compared by using the generalized Wil- 
coxon (Breslow) test. 
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Table 1. Age and Gender Distribution of Patients and 
Control Subjects 
Patients Control Subjects 
(n = 684) (n = 537) 
Leicester 
Subjects (no.) 366 237 
Age (yr) (mean _+ SD) 65.3 _+ 11.6 56,0 _+ 13.1 
Men (%) 67.7% 60.0% 
Sheffield 
Subjects (no.) 318 300 
Age (yr) (mean +_ SD) 66.3 _+ 11.3 29.2 _+ 9.5 
Men (%) 63.2% 52.3% 
Resu l ts  
In all, 684 patients and 537 control subjects from the two 
centers were analyzed (Table 1). More than 90% of the 
patients and control subjects in both centers were white. The 
distribution of the angiotensin-converting enzyme I/D geno- 
types in the two groups is shown in Table 2. The D allele 
frequency in the Leicester and Sheffield control groups was 
52.7% and 54.2%, respectively, and in both centers the geno- 
type frequencies were in agreement with the frequencies 
predicted by the Hardy-Weinberg equilibrium. Despite the 
significant difference in age between the control subjects in the 
two centers (Table 1), the angiotensin-converting enzyme 
genotype frequencies were very similar between the two groups 
(Table 2) and in neither center nor in the overall study group 
did the genotype frequencies differ between patients and 
control subjects (Table 2). The crude odds ratio for myocardial 
infarction for DD compared with II/ID genotypes was 1.06 
(95% CI, 0.82 to 1.36, p = 0.67) and when adjusted for age, 
gender and center the ratio was 1.16 (95% CI 0.82 to 1.65, p = 
0.44). A total of 135 patients (19.7%) had had a previous 
myocardial infarction. The odds ratio remained nonsignificant 
(1.26 [95% CI 0.86 to 1.84], p = 0.25) when the analysis was 
restricted to index (first myocardial infarction) patients and 
control subjects. Likewise, the ratio remained nonsignificant 
when analyzed only for men (odds ratio 1.37 [95% CI 0.88 to 
2.12], p = 0.17) or persons <65 years old (odds ratio 1.06 [95% 
CI 0.70 to 1.62], p = 0.84). 
For the Leicester control group, data on risk factors col- 
lected in the same manner as data for the patients with 
myocardial infarction were available. As expected, reported 
frequencies for hypertension, diabetes, current smoking, pre- 
vious angina and myocardial infarction were all higher in the 
patients (Table 3). Body mass index was similar in the two 
Table 3. Risk Factors for Coronary Heart Disease in Patients and 
Control Subjects in the Leicester Group 
Control 
Patients Subjects 
Risk Factor (n = 366) (n = 237) p Value 
Hypertension 33.3% 16.5% <0.0001 
Diabetes 12.8% 4.2% 0.0005 
Smokers 31.6% 18.0% 0.0002 
Angina 28.9% 7.3% <0.0001 
Previous MI 20.6% 4.7% <0.0001 
Body mass index (kg/m z) 25.8 +_ 4.2 25.4 _+ 3.6 0.31 
Total cholesterol (retool/liter) 5.67 _+ 13 5.63 +_ 1.1 0.79 
HDL cholesterol (retool/liter) 1.22 _+ 0.35 1.19 + 0.33 0.47 
Data presented are mean value _+ SD or percent of group. HDL = high 
density lipoprotein. 
groups. Data on total and HDL cholesterol levels were avail- 
able for 75% of patients and 97% of control subjects and did 
not differ between groups. Although somewhat surprising, the 
finding is similar to that seen in other studies such as the 
Framingham study (26). Cholesterol levels can decrease by up 
to 25% within 48 h after myocardial infarction, and this 
decrease may have masked differences, although efforts were 
made to minimize this effect by measuring lipids on the first 
sample obtained soon after admission. A more likely explana- 
tion is that although the risk of myocardial infarction is clearly 
increased in persons with elevated cholesterol levels, in popu- 
lations with a high average cholesterol level it is not a good 
discriminator between patients and control subjects (26). In 
stepwise logistic regression analyses on the Leicester patients 
and control subjects, the odds ratio for myocardial infarction 
for DD versus II/ID adjusted for the above factors in addition 
to age and gender emained nonsignificant (1.44 [95% CI 0.84 
to 2.46], p = 0.20). In the study by Cambien et al. (5), the 
relative risk of the DD genotype was higher in patients with 
values for body mass index and apolipoprotein B below the 
median values of these variables in the control subjects. 
However, in a comparable analysis, we found no differences 
in the distribution of genotypes between our patients and 
control subjects (p = 0.49) when the analysis was restricted 
to those with body mass index and total cholesterol less than 
the median values for the control subjects (25.3 kg/m 2 and 
5.6 retool/liter, respectively). The odds ratio for DD versus 
II/ID genotypes for this subanalysis was 1.03 (95% CI 0.41 to 
2.59, p = 0.93). 
Characteristics of patients with myocardial infarction com- 
bined from both centers grouped on the basis of angiotensin- 
Table 2. Distribution of Angiotensin-Converting Enzyme Genotypes in Patients and Control Subjects 
Patients Control Subjects 
DD ID II DD ID lI p Value 
Leicester 115 (31%) 167 (46%) 84 (23%) 66 (28%) 118 (50%) 53 (22%) 0.56 
Sheifield 94 (30%) 154 (48%) 70 (22%) 92 (31%) 141 (47%) 67 (22%) 0.93 
Total 209 (31%) 321 (47%) 154 (22%) 158 (30%) 259 (48%) 120 (22%) 0.89 
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Table 4. Characteristics of Patients With Myocardial Infarction According to Angiotensin-Converting 
Enzyme Genotype 
DD ID II 
(n = 209) (n = 321) (n = 154) p Value 
Age (yr) 65.2 ± 12.0 65.7 _+ 11.2 66.5 ± 11.3 0.52 
Men 69% 65% 63% 0.39 
Previous MI 17% 20% 23% 0.29 
Hypertension 34% 35% 31% 0.63 
Diabetes 11% 11% 9% 0.75 
Current smokers 35% 32% 29% 0.39 
Total cholesterol (mmol/liter)* 5.8 -+ 1.3 5.6 _+ 1.l 5.5 -+ 1.4 0.36 
HDL cholesterol (mmol/liter)* 1.2 -+ 0.3 1.2 _+ 0.3 1.3 + 0.4 0.45 
Body mass index (kg/m2) * 26.0 + 4.1 26.2 _+ 3.9 25.0 _+ 3.5 0.12 
Site of infarction 
Anterolateral 47 43 42 0.55 
Inferoposterior 45 52 51 0.26 
Indeterminate 8 5 7 0.32 
Peak CK value (IU/liter) 1,788 ± 1,425 1,933 ± 1,786 1,981 + 1,395 0.71 
*Leicester patients only. Data presented are mean value + SD or percent of group. CK = creatine kinase; HDL = 
high density lipoprotein; MI = myocardial infarction. 
converting enzyme genotype are shown in Table 4. There was 
no difference between the genotype groups with respect o 
either preexisting risk factors or the site or size of myocardial 
infarction as judged by highest creatine kinase levels. For all 
patients, survival status was analyzed at the end of April 1995, 
allowing a median follow-up period of 15 months (range 3 to 
22). By using the National Health Service Central Register, to 
which all deaths in the United Kingdom must be statutorily 
notified, 100% mortality follow-up was obtained. At the cen- 
soring point, 155 of the total cohort of 684 patients had died, 
giving an overall mortality rate of 22.7%. There was no 
difference in mortality between patients with the DD genotype 
and those with the ID/II genotypes (46 [21.8%] or 212 versus 
109 [23.1%] or 472, p = 0.25). Figure 1 shows the cumulative 
mortality curves (calculated by the Kaplan-Meier method) for 
DD and II/ID genotypes. There was no difference in the 
Figure 1. Cumulative mortality curves of patients with myocardial 
infarction with the DD and ID/II angiotensin-converting e zyme gene 
genotypes. The numbers below the X axis indicate the number of 
patients at risk at various time points for the two genotype groups. 
30 ~ . . . .  
~ ~ II/ID genotype 
~ 20 
E D genotype 
l .>_ -5 10 E 
0 [ ~ p=0.62 _ 
0 1 Years 
At risk II/ID 475 356 287 97 
DD 209 165 138 47 
distribution of survival times in the two groups (p = 0.62). The 
difference remained insignificant (p = 0.98) when analysis was 
restricted to index cases. 
Discuss ion 
In this study we provide further insights on the involvement 
of genetic variation at the angiotensin-converting e zyme gene 
locus in cardiovascular disease. The topic has aroused great 
interest since the report of Cambien et al. (5) associating the 
DD genotype at the locus with increased risk of myocardial 
infarction and subsequent reports indicating an association of 
this genotype with other cardiovascular disorders uch as left 
ventricular hypertrophy (27) and restenosis after coronary 
angioplasty (28). The fact that the DD genotype is also 
associated with higher plasma (6) and tissue (29) angiotensin- 
converting enzyme levels compared with ID and II genotypes 
and that angiotensin-converting e zyme plays a crucial role in 
the generation of angiotensin II and the degradation of 
bradykinin, two powerful vasoactive molecules (6), has pro- 
vided a plausible potential intermediary phenotype through 
which its effects on cardiovascular phenotypes could be mani- 
fested. In this context, it is perhaps important to bear in mind 
that the I/D polymorphism, located in intron 16, is probably 
not directly responsible for the effect of the locus on 
angiotensin-converting e zyme levels (and therefore presum- 
ably cardiovascular risk) but is simply acting as a marker for an 
as yet undefined susceptibility polymorphism (Ss) at the locus 
(30). 
Angiotensin-eonverting enzyme gene I/D polymorphism 
and risk of myocardial infarction. Since the report of Cam- 
bien et al. (5), several studies have examined the role of 
angiotensin-converting e zyme I/D polymorphism in coronary 
artery disease by using a variety of approaches (8-19). In 
addition to its association with myocardial infarction in Amer- 
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ican (14) and Japanese (12) subjects, the DD genotype has 
been reported to be more frequent in European (8) and 
Scandinavian (9) children and Australian (15) grandchildren of
persons with a history of coronary events; in Irish subjects with 
a fatal myocardial infarction (10); in French patients with 
non-insulin-dependent diabetes and clinical coronary heart 
disease (11); and in low risk Welsh subjects with coronary heart 
disease identified by use of a Rose questionnaire and ECGs 
(13). Despite these reports, other equally if not more robust 
studies failed to observe any association of the genotype with 
myocardial infarction or angina, or both, in Scandinavian (17), 
American (18) or New Zealand (19) subjects. Disparate results 
have also been reported in relation to other phenotypes 
(28,31,32). In addition, although Ludwig et al. (14) found an 
association with myocardial infarction, their subjects with the 
DD genotype did not have more extensive coronary stenosis, 
thereby suggesting that the genotype may influence not the 
process of atherogenesis but events causing the conversion to 
myocardial infarction and raising doubts about reported asso- 
ciations with manifestations of coronary artery disease not 
related to infarction. A recent study in Japanese subjects (33) 
found subjects with the DD genotype to be more prone to 
ergonovine-induced coronary artery spasm at cardiac atheter- 
ization. As coronary artery spasm may contribute to the 
pathogenesis of myocardial infarction (34), this relation could 
provide an alternative mechanism by which the DD genotype 
may selectively increase the risk of myocardial infarction. 
In this study, in almost 700 predominantly white patients 
with myocardial infarction collected through coronary care 
units in two British cities, we found no excess of the DD 
genotype compared with the level in control subjects. Our 
findings, based on the largest collection of myocardial infarc- 
tion cases o far, concur more with the negative findings of the 
more recent reports (18,19) investigating the role of the 
angiotensin-converting enzyme locus in coronary artery dis- 
ease. An important feature of our study, in contrast to several 
others (5,14,17,19), is that the patients with myocardial infarc- 
tion were recruited consecutively at the time of their acute 
event, thereby reducing the possibility that genotype-related 
selective survival influenced the findings. In addition, our 
follow-up findings suggest that this is probably not so in any 
case (see later). 
A critical feature of any association study is the control 
subjects, who need to provide a reliable estimate of the 
genotype frequencies in the base population from which the 
study patients are recruited. In this study, control subjects were 
recruited in different manners in the two centers. In Leicester, 
they were recruited concurrently with the patients with myo- 
cardial infarction from persons visiting patients admitted to the 
hospital for a wide range of conditions. From information in 
our coronary care unit data base on the age and gender 
distribution of the patients with myocardial infarction admitted 
to the coronary care unit in the previous year, we attempted to 
recruit control subjects of a mix similar to that of the patients 
with probable myocardial infarction, although no individual 
willing to participate was excluded. In Sheffield, a much 
younger cohort of control subjects, again unselected, was 
obtained from hospital workers and students. Despite this 
difference, the genotype distributions were remarkably simi- 
lar in the two control groups and to those of control groups 
reported in several other studies (5,13,14,17-19). Thus, we 
believe that our control cohorts provide a reliable estimate of 
the prevalent distribution of genotypes in their respective 
populations. 
In some studies, the coronary risk associated with the DD 
genotype has been found to be either increased (5) or only 
present (13) in subjects described as at low risk on the basis of 
selected classic risk factors. Because most coronary risk factors 
act additively or synergistically (1,4), the explanation for this 
finding is unclear. In our study we examined several factors but 
were unable to identify any that significantly influenced the 
effect of the angiotensin-converting enzyme genotype, al- 
though our analysis was at reduced power because of a 
combination of smaller group sizes and incomplete informa- 
tion. In this respect, as well as overall, our findings agree with 
those reported by Lindpaintner et al. (18) in subjects of the 
American Physicians tudy. 
The reasons for the discrepant findings in different studies 
remain unclear. In addition to the choice of control subjects 
and the timing of collection of cases (see earlier), possibly 
important genetic and environmental influences may vary 
between populations. For example, Tiret and coworkers (35) 
recently reported synergistic effects of angiotensin-converting 
enzyme and angiotensin-II type 1 receptor gene polymor- 
phisms on risk of myocardial infarction in the patients of the 
original study by Cambien et al. (5). The frequencies ofthe two 
angiotensin-converting e zyme alleles have been shown to vary 
among ethnic populations (36); thus, ethnic heterogeneity 
between patients and control subjects may also confound an 
association. In our study >90% of both patients and control 
subjects were white. Exclusion of nonwhite subjects did not 
affect he result (data not shown), although we cannot exclude 
subtle heterogeneity within the white patients and control 
subjects. As indicated earlier, the I/D polymorphism is proba- 
bly only a marker for the putative susceptibility polymorphism 
and the relation between the two may also vary between 
populations. 
Apart from biologic explanations, tatistical factors need to 
be considered. Despite reaching different conclusions, the 95% 
CI of the odds ratio for DD versus Di l l  genotypes for most of 
the positive and negative studies (5,12,14,18,19) are wide and 
overlap, thus suggesting that the findings may be less hetero- 
geneous than at first sight and partly reflect the statistical 
power of the studies to detect or exclude an effect. Further 
studies are therefore required to investigate the various possi- 
bilities and to determine the precise impact of genetic variation 
at the angiotensin-converting enzyme gene locus on risk of 
myocardial infarction. Nonetheless, what is perhaps equally 
important is whether the marker will be clinically useful in 
evaluating risk of myocardial infarction. From this perspective, 
our study had 90% power (alpha 0.05) to detect a 1.5-fold 
increase in risk of myocardial infarction associated with the 
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DD genotype. Thus, as it stands, our findings suggest that, at 
least in our populations, the angiotensin-converting enzyme 
I/D polymorphism is not a useful marker for assessing the risk 
of myocardial infarction. 
Angiotensin-converting enzyme gene I/D polymorphism 
and prognosis after myocardial infarction. Patients who have 
had a myocardial infarction have a much increased standard- 
ized mortality ratio over the next few years, with further 
cardiovascular events being the main causes of death (37). 
Several factors are known to influence postmyocardial infarc- 
tion prognosis including size of infarction and residual eft 
ventricular function (38). In the last few years, several major 
clinical trials (20-22) have demonstrated a significant improve- 
ment in prognosis in patients treated with inhibitors of 
angiotensin-converting enzyme. The precise mechanisms un- 
derlying the beneficial effects of angiotensin-converting en-
zyme inhibitors remain to be fully elucidated, although a major 
contribution may be through a limitation of infarct expansion 
and cardiac remodeling (39). In experimental studies (40), 
angiotensin-converting e zyme has been shown to be induced 
in the left ventricle in heart failure after myocardial infarction. 
Given the impact of the angiotensin-converting e zyme geno- 
type on angiotensin-converting enzyme levels (6,28), the ob- 
servation that the DD genotype may adversely influence 
prognosis in hypertensive subjects (41), and the finding in an 
exploratory study (42) that he DD genotype may be associated 
with increased ventricular dilation after an anterior myocardial 
infarction, two obvious and clinically important questions 
arise: 1) does the angiotensin-converting enzyme genotype 
influence prognosis after myocardial infarction, and 2) are the 
beneficial effects of angiotensin-converting e zyme inhibitors 
related to the angiotensin-converting enzyme genotype? To 
examine the first question we followed up all our patients with 
myocardial infarction for 3 to 22 months (median 15). Al- 
though the overall mortality rate was similar to that reported in 
other series (20,21), we found no difference in the survival of 
patients with the DD genotype versus those with the II or ID 
genotype. The study had 70% power to detect a 1.5-fold 
increase in mortality during the follow-up period associated 
with the DD genotype. Thus, it would seem that genetic 
variation at the angiotensin-converting enzyme genc locus 
defined by angiotensin-converting e zyme I/D polymorphism 
by itself is not a major determinant of prognosis after myocar- 
dial infarction. However, our study cannot provide an answer 
to the second question. To examine this question correctly, one 
would ideally need to prospectively treat all patients with 
myocardial infarction (or predefined subjects with specific 
features, such as left ventricular dysfunction) with an 
angiotensin-converting enzyme inhibitor, maintain them on 
this treatment for the duration of the study and assess whether 
the prognosis then varies according to angiotensin-converting 
enzyme genotype. Such a study remains to be done, although it
may be possible to obtain some information on this question 
from examining the treated groups in some of the postmyo- 
cardial infarction angiotensin-converting e zyme inhibitor tri- 
als (20-22). 
Limitations of study. Although we found no differences 
in the genotype frequencies in our two control cohorts, which 
also agree with genotype frequencies observed in other white 
populations, the imbalance in age of patients and control 
subjects, particularly inthe Sheffield arm of the study, remains 
problematic, at least theoretically. However, the limited data 
on age-related changes in angiotensin-converting e zyme geno- 
type frequencies are conflicting. In one study, there was a 
decline in DD genotype frequency with age in hypertensive 
patients (41), whereas in another study (43) the DD genotype 
was, paradoxically, overrepresented in older compared with 
younger subjects. The age issue could be particularly relevant 
in women because of the additional impact of the postmeno- 
pausal status on cardiac risk. No studies to date have reported 
a significant effect of the angiotensin-converting e zyme geno- 
type on risk of myocardial infarction in women, and this 
requires pecific evaluation i appropriately powered studies. 
To try to avoid a possible confounding effect of angiotensin- 
converting enzyme genotype on early survival we recruited 
subjects as soon as possible (within 12 h) after admission to the 
coronary care unit. However, it is well recognized that a 
significant proportion of patients with acute myocardial infarc- 
tion die before they enter the hospital. If the DD genotype 
increases the risk not only of myocardial infarction but also of 
very early death, it is possible that an impact of the genotype 
could have been missed despite early recruitment on the 
coronary care unit, as the two effects would tend to cancel out 
each other. There is some retrospective vidence that the 
angiotensin-converting e zyme genotype may increase the risk 
of fatal myocardial infarction (10), but the question of geno- 
type effect on very early mortality can really be answered only 
by population-based prospective studies with postmortem con- 
firmation of cause of death. 
Finally, because we did not systematically collect infor- 
mation on medications that the patients were taking at the 
time of admission or during the follow-up period, we cannot 
exclude the possibility of an interarction between specific 
drugs, especially angiotensin-converting enzyme inhibitors, 
and angiotensin-converting e zyme genotype on either isk of 
myocardial infarction or subsequent survival. 
Conclusions. In summary, in a two-center study of patients 
with myocardial infarction recruited at the time of infarction, 
we were unable to demonstrate a significant effect of variation 
at the angiotensin-converting enzyme gene locus defined by 
the I/D polymorphism on either risk of or prognosis after 
myocardial infarction. We conclude that, at least in the groups 
studied, angiotensin-converting enzyme gene typing will not 
provide clinically valuable information toward assessing the 
risk of myocardial infarction or the prognosis after it. 
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